^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report

Excerpt:
Capmatinib was administered as first-line treatment in an 82-year-old MET-amplified [gene copy number (GCN) 13.5] and MET overexpressed (immunohistochemical staining 3+/3, >50%) NSCLC patient. However, the tumor rapidly progressed and showed primary resistance to capmatinib.
DOI:
10.21037/tlcr-22-176